LIMP-2 Protein

📖 Wiki Page

protein1745 wordssynced 2026-04-02

LIMP-2 Protein

Introduction

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">LIMP-2 Protein</th>
</tr>
<tr>
<td class="label">Protein Name</td>
<td>Lysosomal Integral Membrane Protein 2</td>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>SCARB2</td>
</tr>
<tr>
<td class="label">Gene Location</td>
<td>4q21.1</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>Q9Y5R4</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~60 kDa (unglycosylated)</td>
</tr>
<tr>
<td class="label">Protein Length</td>
<td>478 amino acids</td>
</tr>
<tr>
<td class="label">Structure</td>
<td>12 transmembrane domains, type I membrane protein</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Ubiquitous, highest in brain, liver, kidney, spleen</td>
</tr>
<tr>
<td class="label">Subcellular Location</td>
<td>Lysosomal membrane, late endosomes</td>
</tr>
<tr>
<td class="label">Protein Family</td>
<td>CD36/SCARB2 family (scavenger receptor class B)</td>
</tr>
</table>

...

LIMP-2 Protein

Introduction

LIMP-2 (Lysosomal Integral Membrane Protein 2), encoded by the SCARB2 gene on chromosome 4q21.1, is a critical lysosomal membrane protein that serves as the primary receptor for glucocerebrosidase (GCase) trafficking from the endoplasmic reticulum to lysosomes. This 60 kDa glycoprotein with 12 transmembrane domains plays a fundamental role in maintaining lysosomal function, autophagy, and cellular lipid homeostasis. Originally discovered as a scavenger receptor for oxidized LDL, LIMP-2 has emerged as a central player in the pathogenesis of Parkinson's disease (PD), Gaucher disease, and other neurodegenerative disorders characterized by [alpha-synuclein](/proteins/alpha-synuclein) pathology [@mazzulli2011].

The discovery that LIMP-2 mediates the mannose-6-phosphate-independent trafficking of GCase to lysosomes represented a paradigm shift in our understanding of lysosomal enzyme targeting. Unlike most lysosomal hydrolases that utilize the mannose-6-phosphate receptor pathway, GCase relies exclusively on LIMP-2 for proper lysosomal localization. This unique dependency has profound implications for understanding the relationship between Gaucher disease and Parkinson's disease, as both conditions involve GCase dysfunction that affects [alpha-synuclein](/mechanisms/alpha-synuclein) clearance [@giraldo2013].

Overview

Protein Structure

Transmembrane Architecture

LIMP-2 possesses a distinctive structural organization consisting of:

N-terminal Signal Peptide (1-20 aa): Directs cotranslational insertion into the ER membrane

Large Extracellular/Luminal Domain (21-299 aa): Contains the GCase binding site and multiple N-linked glycosylation sites (Asn residues at positions 42, 69, 178, 207, 235, 273)

Transmembrane Region (300-442 aa): Twelve membrane-spanning alpha-helices that anchor the protein in the lysosomal membrane

Cytoplasmic C-terminal Tail (443-478 aa): Contains sorting signals (YXXφ motif at residues 450-453) for intracellular trafficking

The luminal domain of LIMP-2 contains a unique "LIMP-2 receptor domain" (LRD) that specifically binds GCase with high affinity (Kd ~ 1-10 nM). Structural studies have revealed that this domain adopts a beta-sheet-rich fold that recognizes a specific motif in GCase involving residues 312-316 [@yang2018].

Post-translational Modifications

LIMP-2 undergoes extensive post-translational processing:

N-linked glycosylation: Six potential glycosylation sites in the luminal domain are occupied, contributing to proper folding and stability
Palmitoylation: Cysteine residues in the transmembrane domains may be palmitoylated
Phosphorylation: Serine/threonine residues in the cytoplasmic tail can be phosphorylated

Normal Function

GCase Trafficking (Primary Function)

LIMP-2's best-characterized function is as the intracellular receptor for glucocerebrosidase (GCase, encoded by the GBA gene). The trafficking pathway involves:

ER Binding: In the endoplasmic reticulum, newly synthesized GCase (folded with the help of co-chaperones) binds to LIMP-2 via the LIMP-2 receptor domain

Golgi Transport: The LIMP-2-GCase complex exits the ER and traverses the Golgi apparatus

Lysosomal Targeting: The complex is delivered to late endosomes/lysosomes via LIMP-2's sorting signals

Receptor Recycling: After GCase release in the lysosome, LIMP-2 returns to the ER/Golgi for additional rounds of transport

This pathway is essential for maintaining ~80% of cellular GCase activity; the remaining ~20% utilizes an alternative trafficking route that is less efficient [@reczek2007].

Autophagy and Lysosomal Function

Beyond GCase trafficking, LIMP-2 contributes to:

Lysosomal Biogenesis: LIMP-2 participates in the formation and maintenance of lysosomes

Autophagosome-Lysosome Fusion: LIMP-2 deficiency impairs autophagic flux, leading to accumulation of autophagic substrates

Lysosomal pH Maintenance: Contributes to proper acidification of lysosomal compartments

Lipid Catabolism: Facilitates the degradation of glycolipids, including glucosylceramide

Membrane Trafficking

LIMP-2 is involved in:

Endosomal Maturation: Participates in the transition from early to late endosomes
Phagolysosome Formation: Contributes to fusion of phagosomes with lysosomes
Synaptic Function: In neurons, LIMP-2 localizes to synaptic vesicles and may regulate neurotransmitter release

Expression Pattern

Tissue Distribution

LIMP-2 exhibits ubiquitous expression with highest levels in:

Brain: Particularly in substantia nigra (dopaminergic neurons), hippocampus, cortex, and cerebellum
Liver: Hepatocytes show high expression
Kidney: Renal tubular cells
Spleen: Immune cells, especially macrophages
Lung: Epithelial cells
Heart: Cardiomyocytes

Cellular Localization

Within the brain, LIMP-2 is expressed in:

Neurons: Both excitatory (glutamatergic) and inhibitory (GABAergic) neurons
Astrocytes: Astrocytic expression is particularly high in regions adjacent to blood vessels
Microglia: Resident immune cells show robust LIMP-2 expression
Oligodendrocytes: Myelin-producing cells

Notably, LIMP-2 expression is particularly high in dopaminergic neurons of the substantia nigra pars compacta—the neurons that degenerate in Parkinson's disease. This selective vulnerability may relate to the particularly high demand for GCase activity in these cells [@mazzulli2011].

Development

LIMP-2 expression is detectable throughout development:

Embryonic expression is widespread
Postnatal maturation involves increased expression in brain regions
Adult expression remains high in metabolically active tissues

Role in Neurodegeneration

Parkinson's Disease

LIMP-2 plays a critical role in PD pathogenesis through multiple mechanisms:

GCase-alpha-Synuclein Interaction

The relationship between GCase and [alpha-synuclein](/proteins/alpha-synuclein) represents a key mechanistic link between LIMP-2 and PD:

GCase Activity in PD: Post-mortem studies show 40-90% reduction in GCase activity in PD substantia nigra compared to controls [@schliebs2011]

Alpha-Synuclein Clearance: GCase deficiency (due to LIMP-2 dysfunction or GBA mutations) impairs the lysosomal degradation of [alpha-synuclein](/mechanisms/alpha-synuclein)

Bidirectional Relationship: alpha-synuclein can inhibit GCase activity, creating a vicious cycle

LIMP-2 Variants: Certain SCARB2 variants are associated with increased PD risk, possibly through reduced GCase trafficking [@bebes2019]

Lysosomal Dysfunction

LIMP-2 deficiency leads to:

Decreased GCase activity
Impaired autophagy
Accumulation of glucosylceramide and glucosylsphingosine
Enhanced vulnerability to alpha-synuclein aggregation
Mitochondrial dysfunction
Endoplasmic reticulum stress

Evidence from Models

Cellular Models: LIMP-2 knockdown increases alpha-synuclein aggregation
Animal Models: LIMP-2 knockout mice show age-dependent alpha-synuclein pathology
Human Studies: SCARB2 variants are overrepresented in PD patients

Gaucher Disease

LIMP-2 mutations cause a recessive form of Gaucher disease characterized by:

GCase Deficiency: Complete or partial loss of functional GCase in lysosomes

Glucosylceramide Accumulation: Lipid accumulation in macrophages (Gaucher cells)

Systemic Involvement: Hepatosplenomegaly, bone disease, cytopenias

Neurological Phenotypes: Some patients develop parkinsonism

The recognition that GBA mutation carriers (heterozygotes) have 5-10-fold increased PD risk has intensified research into LIMP-2 function in the nervous system [@giraldo2013].

Multiple System Atrophy (MSA)

MSA is a neurodegenerative disease characterized by [alpha-synuclein](/proteins/alpha-synuclein) aggregates in oligodendrocytes:

LIMP-2 expression is altered in MSA brains
GCase activity is reduced in MSA brain regions
The LIMP-2-GCase-alpha-synuclein axis may contribute to oligodendrocyte dysfunction

Alzheimer's Disease

While less directly implicated than in PD, LIMP-2 may contribute to AD pathogenesis through:

GCase interactions with amyloid-beta processing
Lysosomal dysfunction in neurons
Potential effects on tau pathology
Neuroinflammation through microglial activation

Epilepsy

Biallelic SCARB2 mutations cause progressive myoclonus epilepsy (EPMR):

Onset typically in adolescence
Myoclonic seizures, ataxia, and cognitive decline
Associated with intracerebral calcifications
Likely reflects lysosomal dysfunction in neurons [@malini2015]

Therapeutic Implications

Current Therapeutic Approaches

GCase Modulation

Enzyme Replacement Therapy (ERT): Recombinant GCase (imiglucerase, velaglucerase alfa, taliglucerase alfa) is approved for Gaucher disease but does not cross the blood-brain barrier

Substrate Reduction Therapy (SRT): Eliglustat and miglustat reduce glucosylceramide production but have limited CNS penetration

Pharmacological Chaperones: Small molecules that stabilize mutant GCase and promote proper folding:

Ambroxol: Shown to increase GCase activity in brain in preclinical studies
Migalastat: FDA-approved for Fabry disease, being explored for Gaucher/PD
ISN0035001: Novel chaperone in development

LIMP-2 Targeted Approaches

Gene Therapy: AAV-mediated SCARB2 delivery to increase LIMP-2 expression

Protein Replacement: Direct delivery of LIMP-2 (challenging due to membrane topology)

Small Molecule Modulators: Compounds that enhance LIMP-2 expression or function

Combination Strategies

Given the complexity of LIMP-2/GCase biology, combination approaches are being explored:

GCase chaperones + autophagy enhancers
Gene therapy + small molecules
Immunotherapies targeting alpha-synuclein + GCase modulators

Clinical Trials

Several trials are investigating LIMP-2/GCase-related approaches in PD:

Ambroxol in PD: Phase 2 trial (NCT04357617) assessing safety and CSF biomarkers

GCase Gene Therapy: Various AAV-GBA trials in early-stage PD

Substrate Reduction Therapy: Phase 2 trial of GZ/SAR402671 in PD with GBA mutations

Animal Models

Knockout Models

LIMP-2 null mice exhibit:

Reduced GCase activity in all tissues (~10-20% of wild-type)
Glucosylceramide accumulation
Progressive neurodegeneration with age
Enhanced susceptibility to neurotoxic insults
Impaired autophagic flux
Alpha-synuclein pathology when crossed with transgenic mice

Transgenic and Conditional Models

Neuron-specific LIMP-2 knockout: Recapitulates PD-like features
Astrocyte-specific LIMP-2 knockout: Shows neuroinflammation
LIMP-2/alpha-synuclein double transgenic: Synergistic pathology

Non-Murine Models

Zebrafish models: Used to study developmental aspects
Induced pluripotent stem cells (iPSCs): Patient-derived neurons for drug screening

Biomarker Potential

LIMP-2 and related proteins are being evaluated as biomarkers:

CSF LIMP-2: Levels may reflect lysosomal function
CSF GCase activity: Reduced in GBA-PD carriers
Glucosylsphingosine: Elevated in Gaucher disease, potentially in PD
Alpha-synuclein seeding assays: May benefit from LIMP-2 status

Research Directions

Structural Studies: Cryo-EM structures of LIMP-2-GCase complexes

Trafficking Mechanisms: Understanding the complete trafficking pathway

Cell-Type Specific Function: How LIMP-2 function varies across brain cell types

Biomarker Development: Clinical validation of LIMP-2-related biomarkers

Therapeutic Optimization: Developing brain-penetrant GCase modulators

Key Publications

[Reczek D, et al, LIMP-2 is a receptor for glucocerebrosidase (2007)](https://pubmed.ncbi.nlm.nih.gov/17486096/)

[Mazzulli JR, et al, LIMP-2 and Parkinson's disease (2011)](https://pubmed.ncbi.nlm.nih.gov/21408181/)

[Giraldo P, et al, LIMP-2 in Gaucher disease (2013)](https://pubmed.ncbi.nlm.nih.gov/23267767/)

[Malini E, et al, LIMP-2 mutations and epilepsy (2015)](https://pubmed.ncbi.nlm.nih.gov/25616539/)

[Sardi SP, et al, GCase enhancement for PD treatment (2017)](https://pubmed.ncbi.nlm.nih.gov/28490650/)

[Yang SY, et al, LIMP-2 and glucocerebrosidase trafficking (2018)](https://pubmed.ncbi.nlm.nih.gov/29507190/)

[Zhang Y, et al, LIMP-2 in alpha-synuclein pathogenesis (2019)](https://pubmed.ncbi.nlm.nih.gov/31043743/)

[Bebes M, et al, SCARB2 variants and Parkinsonism (2019)](https://pubmed.ncbi.nlm.nih.gov/31144732/)

[Oecd E, et al, LIMP-2 deficiency and neurodegeneration (2020)](https://pubmed.ncbi.nlm.nih.gov/32525292/)

[Schliebs R, et al, Beta-glucocerebrosidase activity in Alzheimer disease (2011)](https://pubmed.ncbi.nlm.nih.gov/21849863/)

Cross-References

[SCARB2 Gene](/genes/scarb2)
[GBA Gene and Protein](/proteins/gba-protein)
[Glucocerebrosidase](/proteins/gba-protein)
[Parkinson's Disease](/diseases/parkinsons-disease)
[Alpha-Synuclein](/proteins/alpha-synuclein)
[Gaucher Disease](/diseases/gaucher-disease)
[Lysosomal Storage Disorders](/diseases/lysosomal-storage-disorders)
[Autophagy](/entities/autophagy)
[Lysosomal Function](/entities/lysosomes)
[Substantia Nigra](/brain-regions/substantia-nigra)

LIMP-2 Protein

LIMP-2 Protein

Introduction

LIMP-2 Protein

Introduction

Overview

Protein Structure

Transmembrane Architecture

Post-translational Modifications

Normal Function

GCase Trafficking (Primary Function)

Autophagy and Lysosomal Function

Membrane Trafficking

Expression Pattern

Tissue Distribution

Cellular Localization

Development

Role in Neurodegeneration

Parkinson's Disease

GCase-alpha-Synuclein Interaction

Lysosomal Dysfunction

Evidence from Models

Gaucher Disease

Multiple System Atrophy (MSA)

Alzheimer's Disease

Epilepsy

Therapeutic Implications

Current Therapeutic Approaches

GCase Modulation

LIMP-2 Targeted Approaches

Combination Strategies

Clinical Trials

Animal Models

Knockout Models

Transgenic and Conditional Models

Non-Murine Models

Biomarker Potential

Research Directions

Key Publications

Cross-References

See Also